In-silico analysis of TMEM2 as a pancreatic adenocarcinoma and cancer-associated fibroblast biomarker, and functional characterization of NSC777201, for targeted drug development.

Saved in:
Bibliographic Details
Title: In-silico analysis of TMEM2 as a pancreatic adenocarcinoma and cancer-associated fibroblast biomarker, and functional characterization of NSC777201, for targeted drug development.
Authors: Srivastava P; The Program for Translational Medicine, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan., Yadav VK; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Shuang Ho Hospital New Taipei 23561, Taiwan.; Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei 110, Taiwan., Chang TH; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; Clinical Big Data Research Center, Taipei Medical University Hospital Taipei 110, Taiwan., Su EC; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan., Lawal B; UPMC Hillman Cancer Center, University of Pittsburgh Pittsburgh, PA 15232, USA.; Department of Pathology, University of Pittsburgh Pittsburgh, PA 15213, USA., Wu AT; The Program for Translational Medicine, Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; Graduate Institute of Medical Sciences, National Defense Medical Center Taipei 114, Taiwan.; The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University Taipei 110, Taiwan.; Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University Taipei 11031, Taiwan., Huang HS; Graduate Institute of Medical Sciences, National Defense Medical Center Taipei 114, Taiwan.; Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University Taipei 110, Taiwan.; PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Academia Sinica Taipei 11031, Taiwan.; School of Pharmacy, National Defense Medical Center Taipei 11490, Taiwan.; PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University Taipei 11031, Taiwan.
Source: American journal of cancer research [Am J Cancer Res] 2024 Jun 15; Vol. 14 (6), pp. 3010-3035. Date of Electronic Publication: 2024 Jun 15 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: e-Century Pub. Corp Country of Publication: United States NLM ID: 101549944 Publication Model: eCollection Cited Medium: Print ISSN: 2156-6976 (Print) Linking ISSN: 21566976 NLM ISO Abbreviation: Am J Cancer Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2156-6976
DOI:10.62347/CHXD6134